🇪🇺 Elucirem in European Union

EMA authorised Elucirem on 7 December 2023

Marketing authorisation

EMA — authorised 7 December 2023

  • Application: EMEA/H/C/005626
  • Marketing authorisation holder: Guerbet
  • Local brand name: Elucirem
  • Indication: This medicinal product is for diagnostic use only.Elucirem is indicated in adults and children from birth for contrast-enhanced magnetic resonance imaging (MRI) to improve detection and visualization of pathologies with disruption of the blood-brain-barrier (BBB) and/or abnormal vascularity of:- the brain, spine, and associated tissues of the central nervous system (CNS);- the liver, kidney, pancreas, breast, lung, prostate, and musculoskeletal system.It should be used only when diagnostic information is essential and not available with unenhanced MRI.
  • Status: approved

Read official source →

Elucirem in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in European Union

Frequently asked questions

Is Elucirem approved in European Union?

Yes. EMA authorised it on 7 December 2023.

Who is the marketing authorisation holder for Elucirem in European Union?

Guerbet holds the EU marketing authorisation.